Prosecution Insights
Last updated: August 18, 2026

Examiner: CHANDRAKUMAR, NIZAL S

Tech Center 1600 • Art Units: 1625 1674

This examiner grants 73% of resolved cases

Performance Statistics

72.7%
Allow Rate
+12.7% vs TC avg
1,862
Total Applications
+18.3%
Interview Lift
831
Avg Prosecution Days
Based on 1774 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
11.1%
§102 Novelty
29.1%
§103 Obviousness
36.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17794003 MECHANOCHEMICAL SNAr REACTIONS Non-Final OA nChain Licensing AG
18547871 DEVELOPMENT OF PRMT-TARGETING THERAPY TO ENHANCE EGFR-TARGETING DRUG EFFICACY IN NSCLC Non-Final OA The Regents of the University of California
18111350 RESPONSE-GUIDED HCV THERAPY Non-Final OA Emory University
19365360 OPHTHALMIC FORMULATIONS Non-Final OA PELTHOS THERAPEUTICS INC.
18853224 IMMUNE MODULATORY AGENTS Non-Final OA PRESIDENT AND FELLOWS OF HARVARD COLLEGE
18700643 METHODS OF TREATING DISEASES ASSOCIATED WITH SENESCENT CELL ACCUMULATION Non-Final OA University of Florida Research Foundation, Incorporated
18604926 PHARMACEUTICAL COMPOSITIONS COMPRISING APRACLONIDINE FOR OCULAR REDNESS RELIEF Non-Final OA ALCON INC.
17760181 Agent For Treating Or Preventing Pancreatic Fistula Non-Final OA NOF CORPORATION
17836814 ORAL PRODUCTS WITH REDUCED IRRITATION Final Rejection NICOVENTURES TRADING LIMITED
18856717 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Non-Final OA SANOFI
17776922 METHODS OF INDUCING OR ENHANCING FARNESOID X RECEPTOR (FXR)-MEDIATED TRANSCRIPTIONAL RESPONSE Final Rejection YALE UNIVERSITY
18777339 Benzimidazole Pyridine Derivatives Non-Final OA Hoffmann-La Roche Inc.
18248232 TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Non-Final OA The Research Foundation for The State University of New York
18689222 METHOD FOR PRODUCING COMPOUND Non-Final OA Mitsubishi Gas Chemical Company, Inc.
18573813 COMPOUNDS FOR MODULATING MYCOBACTERIUM TUBERCULOSIS RESPONSE Non-Final OA Rutgers, The State University of New Jersey
17787964 METHOD FOR PRODUCING SOLID ELECTROLYTE Final Rejection IDEMITSU KOSAN CO.,LTD.
18255749 OIL-IN-WATER EMULSIFIED COMPOSITION Non-Final OA KAO CORPORATION
17800049 HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS Non-Final OA Givaudan SA
18267925 AMORPHOUS SOLID DISPERSIONS Non-Final OA UCB Biopharma SRL

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month